+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030- Product Image
Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011312
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chemotherapy Induced Nausea & Vomiting Treatment Market grew from USD 3.13 billion in 2024 to USD 3.34 billion in 2025. It is expected to continue growing at a CAGR of 6.57%, reaching USD 4.59 billion by 2030.

Setting the Stage for Advances in CINV Management

Chemotherapy induced nausea and vomiting represent a formidable challenge in oncology care, significantly impacting patient quality of life and treatment adherence. As cancer therapies evolve and patient populations grow more diverse, the management of these distressing side effects demands increasingly sophisticated approaches. This executive summary offers a structured overview that underscores both the complexity of CINV management and the opportunities for innovation in pharmaceutical development, clinical practice, and strategic investment.

By framing the context within the broader oncology support care landscape, the introduction highlights the critical role that effective antiemetic therapies play in enhancing patient outcomes. The narrative recognizes how breakthroughs in molecular pharmacology, coupled with evolving clinical guidelines, have reshaped therapeutic protocols. At the same time, it acknowledges persistent gaps in access, patient response variability, and the economic burdens borne by healthcare systems. Through this lens, the stage is set for an in-depth exploration of transformative shifts, regulatory influences, and market dynamics that collectively chart the future of CINV treatment.

Redefining the CINV Landscape Through Innovative Shifts

Over the past few years, the landscape of CINV treatment has been redefined by breakthroughs in targeted antiemetic agents and expanded clinical protocols. Pivotal clinical data surrounding novel NK1 receptor antagonists have demonstrated superior control of delayed emesis, prompting updates to international treatment guidelines. At the same time, the integration of combination regimens tailored to patient-specific emetic risk profiles has elevated standard-of-care benchmarks in oncology centers worldwide.

Advancements in pharmacogenomic profiling are now informing personalized antiemetic strategies, enabling clinicians to predict therapeutic response and optimize dosing. Concurrently, digital health platforms that monitor real-time symptom reporting have strengthened patient engagement and adherence to prophylactic regimens. These technological innovations, alongside an increasing emphasis on value-based care, have initiated a paradigm shift from reactive management to anticipatory, data-driven intervention frameworks. As these transformative shifts gain traction, they pave the way for more effective, patient-centric approaches to CINV management.

Tariff Impacts Reshaping the US CINV Treatment Market

In 2025, adjustments to United States tariff structures have created ripples across pharmaceutical supply chains, directly impacting the availability and pricing of critical antiemetic agents. Imported active pharmaceutical ingredients face revised duty rates, altering the cost calculus for manufacturers reliant on overseas raw materials. These changes have triggered supply adjustments and- in some cases-accelerated the search for domestic API sources to mitigate exposure to tariff volatility.

On the distribution front, tightening margins have influenced procurement decisions among hospital pharmacies and specialty treatment centers. Stakeholders have responded by reassessing supplier agreements and exploring strategic partnerships to ensure continuity of patient access. Simultaneously, regulatory agencies and industry associations are engaging in advocacy efforts to streamline import processes and secure tariff exemptions for life-saving medications. These combined pressures underscore the importance of agility in navigating evolving trade policies and safeguarding the resilience of CINV treatment networks.

Unveiling Core Segments Driving CINV Therapeutics

A nuanced understanding of patient segments reveals that drug class differentiation remains fundamental to shaping therapeutic strategies. The class of 5-HT3 receptor antagonists, encompassing granisetron, ondansetron, palonosetron, and ramosetron, continues to serve as the cornerstone of acute phase prevention. Complementing these agents, corticosteroids such as dexamethasone and methylprednisolone enhance efficacy across both acute and delayed phases. Dopamine receptor antagonists, represented by metoclopramide and prochlorperazine, occupy specific niches where receptor modulation offers alternative pathways to control refractory symptoms. The newest class, NK1 receptor antagonists including aprepitant and fosaprepitant, provides robust prophylaxis against delayed emesis, reshaping combination protocols.

Route of administration also delineates critical patient subgroups, with intravenous formulations ensuring immediate bioavailability in clinical settings and oral options offering convenience for outpatient care. Therapy type emerges as another axis of differentiation: monotherapy remains prevalent for low- to moderate-risk cases, while combination regimens-whether dual protocols pairing 5-HT3 antagonists with NK1 agents or steroids, or triple combinations that unify all three-serve high-risk populations. These regimens are crafted to balance efficacy, safety, and patient tolerability.

Distribution pathways further segment the market, as hospital pharmacies manage bulk procurement for inpatient oncology wards, online pharmacies address patient demand for home-based refills, and retail pharmacies cater to walk-in prescriptions following outpatient visits. End-user segmentation highlights distinct care settings, from home care environments where self-administered oral therapies predominate to hospital infusion centers and specialty oncology clinics that rely heavily on intravenous delivery. Emetic risk stratification remains a cornerstone of regimen selection, categorizing chemotherapy protocols into high, moderate, low, or minimal risk tiers to guide prophylactic intensity. Patient age groups, spanning adult and pediatric cohorts, introduce additional layers of clinical and dosing considerations, necessitating tailored formulations and support measures across the demographic spectrum.

Regional Dynamics Shaping CINV Markets

A regional lens reveals diverse market drivers and adoption patterns across the Americas, Europe, the Middle East & Africa, and Asia-Pacific. In the Americas, established healthcare infrastructures and well-defined reimbursement frameworks have facilitated rapid uptake of novel antiemetic therapies, with specialty clinics and comprehensive cancer centers championing evidence-based protocols. Contrastingly, Europe, the Middle East & Africa presents a mosaic of regulatory environments and reimbursement schemes, propelling stakeholders to navigate complex market entry pathways while leveraging collaborative partnerships to broaden therapeutic access.

Across Asia-Pacific, dynamic economic growth and expanding healthcare budgets have spurred investment in oncology support care, although variances in public and private insurance coverage influence patient out-of-pocket costs. Each region exhibits unique supply chain considerations, from API sourcing strategies in North America to distribution network optimizations in Europe, and from regulatory harmonization efforts in the Gulf Cooperation Council to local manufacturing initiatives in Southeast Asia. Recognizing these regional dynamics is essential for aligning product launches, pricing strategies, and education campaigns with the distinct needs of healthcare providers and patients in each territory.

Key Players Steering CINV Treatment Evolution

Leading pharmaceutical innovators and generics manufacturers alike have intensified their focus on antiemetic portfolios, driving collaborations and pipeline accelerations. Established multinationals have leveraged their global reach to secure partnerships with contract manufacturing organizations, ensuring scalable production of both first-generation 5-HT3 antagonists and next-generation NK1 compounds. Concurrently, mid-sized specialty firms are differentiating through novel fixed-dose combination products that simplify dosing schedules and enhance patient convenience.

Biotechnology ventures have entered the fray, exploring novel mechanisms of action and sustained-release formulations to address unmet needs in delayed emesis. Strategic alliances between pharma and digital health startups are emerging, integrating symptom tracking applications that reinforce adherence and provide real-world data for post-market surveillance. Meanwhile, regional distributors and pharmacy chains are forging exclusive supply agreements that fortify their positions within hospital and retail networks. This confluence of innovation, collaboration, and distribution agility characterizes the competitive landscape and underscores the importance of strategic foresight in capturing value across the CINV continuum.

Strategic Roadmap for CINV Market Leadership

Industry leaders should prioritize a multifaceted strategy to capitalize on emerging opportunities in CINV management. Investing in R&D that advances sustained-release and targeted-delivery platforms will differentiate product offerings and respond to the growing demand for patient-centric therapies. Establishing partnerships with academic institutions and clinical networks can accelerate evidence generation and support guideline adoption across diverse practice settings. It is equally imperative to cultivate flexible supply chains, incorporating dual sourcing of raw materials and proactive tariff mitigation tactics to minimize cost fluctuations and ensure uninterrupted production.

Furthermore, integrating digital health solutions into antiemetic programs will foster greater patient engagement and generate actionable insights. Commercial teams must align pricing strategies with regional reimbursement landscapes, deploying localized value propositions that resonate with payers, providers, and patient advocacy groups. Leadership in market access will hinge on demonstrating not just clinical efficacy but also real-world economic benefits, paving the way for preferred formulary positions and long-term volume growth. By adopting these recommendations, organizations will reinforce their market positions and drive sustained advancement in clinical care.

Rigorous Approach to CINV Research Methodology

The research underpinning this analysis employs a robust methodology designed to capture comprehensive market intelligence. Primary data were gathered through in-depth interviews with oncologists, pharmacists, hospital procurement specialists, and industry executives across key regions. Secondary sources included peer-reviewed journals, conference proceedings, regulatory filings, and trade association publications to ensure a holistic view of clinical developments, policy changes, and competitive dynamics.

Analytical frameworks such as SWOT assessments, value chain analyses, and regulatory impact evaluations were applied to distill critical insights. Segmentation analyses were validated against real-world usage patterns, while tariff impact studies incorporated trade data and policy documentation. Rigorous triangulation techniques ensured data integrity and minimized bias, providing decision-makers with a reliable foundation for strategic planning. The result is a nuanced perspective that balances macroeconomic forces, clinical innovation, and stakeholder priorities in the evolving CINV treatment landscape.

Closing Thoughts on CINV Future Trajectories

As chemotherapy protocols continue to advance, the imperative to manage nausea and vomiting remains as critical as ever. The landscape of antiemetic therapy is characterized by rapid innovation, complex regulatory environments, and shifting trade dynamics. By synthesizing drug class evolution, administration routes, therapy types, and regional intricacies, this summary provides a clear vision of how stakeholders can navigate current challenges and harness growth opportunities.

Looking forward, continued investment in personalized medicine, digital integration, and supply chain resilience will define the next wave of progress. Collaboration across the healthcare ecosystem-spanning manufacturers, providers, payers, and patient advocates-will be essential to translate research breakthroughs into tangible improvements in patient care. Ultimately, the collective action of industry leaders will shape a future where CINV is effectively prevented, managed, and, one day, eradicated.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • 5-HT3 Receptor Antagonists
      • Granisetron
      • Ondansetron
      • Palonosetron
      • Ramosetron
    • Corticosteroids
      • Dexamethasone
      • Methylprednisolone
    • Dopamine Receptor Antagonists
      • Metoclopramide
      • Prochlorperazine
    • NK1 Receptor Antagonists
      • Aprepitant
      • Fosaprepitant
  • Route Of Administration
    • Intravenous
    • Oral
  • Therapy Type
    • Combination Therapy
      • Dual Regimen
        • 5-HT3 And NK1
        • 5-HT3 And Steroid
        • NK1 And Steroid
      • Triple Regimen
    • Monotherapy
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
  • Emetic Risk
    • High
    • Low
    • Minimal
    • Moderate
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Helsinn Healthcare SA
  • GlaxoSmithKline plc
  • Heron Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Mylan N.V.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class
8.1. Introduction
8.2. 5-HT3 Receptor Antagonists
8.2.1. Granisetron
8.2.2. Ondansetron
8.2.3. Palonosetron
8.2.4. Ramosetron
8.3. Corticosteroids
8.3.1. Dexamethasone
8.3.2. Methylprednisolone
8.4. Dopamine Receptor Antagonists
8.4.1. Metoclopramide
8.4.2. Prochlorperazine
8.5. NK1 Receptor Antagonists
8.5.1. Aprepitant
8.5.2. Fosaprepitant
9. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Therapy Type
10.1. Introduction
10.2. Combination Therapy
10.2.1. Dual Regimen
10.2.1.1. 5-HT3 And NK1
10.2.1.2. 5-HT3 And Steroid
10.2.1.3. NK1 And Steroid
10.2.2. Triple Regimen
10.3. Monotherapy
11. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Emetic Risk
13.1. Introduction
13.2. High
13.3. Low
13.4. Minimal
13.5. Moderate
14. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Patient Age Group
14.1. Introduction
14.2. Adult
14.3. Pediatric
15. Americas Chemotherapy Induced Nausea & Vomiting Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Chemotherapy Induced Nausea & Vomiting Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Chemotherapy Induced Nausea & Vomiting Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Merck & Co., Inc.
18.3.2. Eisai Co., Ltd.
18.3.3. Helsinn Healthcare SA
18.3.4. GlaxoSmithKline plc
18.3.5. Heron Therapeutics, Inc.
18.3.6. Teva Pharmaceutical Industries Ltd.
18.3.7. Sandoz International GmbH
18.3.8. Mylan N.V.
18.3.9. Dr. Reddy's Laboratories Ltd.
18.3.10. Sun Pharmaceutical Industries Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 84. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 85. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 86. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 90. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 91. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 94. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 165. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 169. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 170. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 173. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 183. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 186. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 202. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 203. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 204. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 205. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 208. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 209. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 212. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 222. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 225. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILL

Companies Mentioned

The companies profiled in this Chemotherapy Induced Nausea & Vomiting Treatment market report include:
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Helsinn Healthcare SA
  • GlaxoSmithKline plc
  • Heron Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Mylan N.V.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.34 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.59 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Chemotherapy Induced Nausea And Vomiting - Pipeline Insight, 2025 - Product Image

Chemotherapy Induced Nausea And Vomiting - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Chemotherapy-induced Nausea and Vomiting Drugs - Global Strategic Business Report - Product Image

Chemotherapy-induced Nausea and Vomiting Drugs - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025 - Product Image

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chemotherapy-induced nausea and vomiting (CINV) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chemotherapy-induced nausea and vomiting (CINV) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
2025 Global Forecast for Chemotherapy-Induced Nausea And Vomiting (Cinv) Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Chemotherapy-Induced Nausea And Vomiting (Cinv) Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Chemotherapy Induced Nausea Drug Market

Chemotherapy Induced Nausea (CIN) drugs are a type of oncology drug used to treat the nausea and vomiting caused by chemotherapy. CIN drugs are typically administered before, during, or after chemotherapy to reduce the severity of nausea and vomiting. Common CIN drugs include 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These drugs work by blocking the action of serotonin and other chemicals in the brain that cause nausea and vomiting. CIN drugs are an important part of cancer treatment, as they can help reduce the side effects of chemotherapy and improve the quality of life for cancer patients. CIN drugs are available in both oral and intravenous forms, and are often used in combination with other anti-nausea medications. Companies in the CIN drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.